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ABSTRACT
Partial D2-like receptor agonists act as functional
antagonists when given during periods of high
dopaminergic tone (e.g., when self-administering
cocaine). The ability of a partial D2-like agonist
(e.g., terguride) to block the induction and
expression of cocaine-induced behavioral sensitization
was assessed in preweanling rats. The ability of
terguride alone to produce a sensitized response was
also investigated. It was hypothesized that terguride
would block induction and eventual expression of
cocaine-induced behavioral sensitization. It was
further hypothesized that terguride alone would not
produce behavioral sensitization. Subjects were 242
(n=8 per group) male and female rat pups of Sprague-
Dawley descent. In Experiments 1 and 2, rats were
injected with terguride (0.1-1.6 mg/kg) during the
pre-exposure phase to determine if a partial D2-like
agonist would block induction and eventual expression
of cocaine-induced behavioral sensitization. In
Experiment 3, rats were injected with terguride (0.2-
0.8) on test day to determine whether expression of
iii
cocaine-induced behavioral sensitization would be
blocked by acute treatment with a partial D2-like
agonist. The ability of terguride to produce
behavioral sensitization in and of itself was examined
in Experiment 4. In this experiment, rats were
injected with terguride (0.4, 0.8, or 1.6 mg/kg) 
during the pre-exposure phase, and received a test day
challenge injection of saline or 0.4 mg/kg terguride.
Interestingly, terguride reduced the locomotor
activity of cocaine-treated rats during the
pretreatment phase, but the partial D2-like agonist
did not block the induction of behavioral
sensitization. When given on the test day, terguride 
decreased locomotor activity. This may indicate that
a partial D2-like agonist is capable of blocking the
expression of cocaine-induced behavioral
sensitization, but it is more likely that terguride
reduced the acute locomotor-stimulating properties of
cocaine. Repeated treatment with terguride did not
produce behavioral sensitization. Because partial D2-
like agonists attenuate reward, it had been proposed
that this class of drugs may be an effective
pharmacotherapy for psychostimulant abuse. However,
iv
the present results bring into question whether
terguride will prove effective as a pharmacotherapy
for psychostimulant addiction, because the
sensitization component of the addiction process is
apparently unaffected by partial D2-like agonist
treatment.
v
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CHAPTER ONE
OVERVIEW
The worldwide use of the highly addictive
psychostimulant drug cocaine is increasing at an
alarming rate among both adults and children (National
Institute of Drug Abuse, 1999). Cocaine is one of the
most addictive substances known, and its use has major
social and economic implications that cross cultural
and societal lines (National Institute of Drug Abuse,
1999). Approximately 1 out of 10 people who use
cocaine develop a severe form of addiction that
involves incessant craving and chronic relapse (Di
Chiara, 1995; Robinson & Berridge, 1993). Due to
chemical changes in brain activity, addicted
cocaine users continue taking the drug despite serious
health and social conseguences (National Institute of
Drug Abuse, 1999; Robinson & Berridge, 1993).
Research has established that dopamine is one of
the major neurotransmitters involved in the
neurobiological substrates of drug addiction and
relapse (for reviews, see Bozarth, 1987; Di Chiara,
1999). Dopamine synapses are a critical component of
1
endogenous reward systems in the brain, and are
important for sex drive, mood, and locomotion (Koob,
1992a, 1992b; Wise & Bozarth, 1984). Not
surprisingly, cocaine, as well as other
psychostimulants, are reinforcing because they
activate endogenous reward systems. Cocaine's
mechanism of action is well established, as cocaine
blocks the dopamine reuptake pump, resulting in large
amounts of dopamine in the synaptic cleft (see Figure
1) (Reith, Sershen, & Lajtha, 1980). In this way,
cocaine indirectly enhances dopamine neuronal
transmission (Cooper, Bloom, & Roth, 1996; Reith et
al., 1980). This increased neuronal transmission is
responsible for the sense of pleasure and excitement
that cocaine users report, as well as increased
locomotion and stereotyped movement (Koob, 1992a,
1992b; Robinson & Berridge, 1993; Shippenberg,
LeFevour, & Heidbreder, 1996).
Kebabian and Caine (1979) first described two
dopamine receptors subtypes (Di and D2) based on
biochemical action. More recently, these receptor
subtypes have been further delineated into the Di-like
(Di and D5) and D2-like (D2, D3, and D4) families of
2
Figure 1. Action of Cocaine on 
Dopamine Neuron. Cocaine binds to the 
reuptake pump, preventing reuptake of 
dopamine into the cell.
3
receptors (Clark & White, 1987). Activation of the Dr
like receptor subtype stimulates' adenylyl cyclase,
whereas activation of the D2-like receptor subtype
inhibits adenylyl cyclase (Clark & White, 1987).
Besides differentially affecting adenylyl cyclase
activity, Di-like and D2-like receptors uniquely impact
behavior. For example, stimulation of the Di-like
receptor by a direct agonist drug, such as SKF 38393,
increases horizontal locomotor activity, whereas
stimulation of the D2-like receptor increases
stereotypy (Arnt, Hyttel, & Perregaard, 1987; Hu,
Brooderson, & White, 1992; Molloy & Waddington, 1985,
1987). Evidence also shows that Di-like and D2-like
receptors are differentially involved in mediating
reward (Beninger & Miller, 1998; Koechling, Colle, &
Wise, 1988). For example, reinforced responding can
be blocked using a dopamine Di-like receptor agonist
(e.g., SCH 23390), whereas sulpiride, a D2-like
receptor antagonist, does not block reinforced
responding (McDougall, Crawford, & Nonneman, 1992;
McDougall, Nonneman, & Crawford, 1991; Nakajima, 1986;
Nakajima & McKenzie, 1986). These findings provide
evidence that Di-like receptors are more intimately
4
involved in reward processes than are D2~like receptors
(for review, see Miller, -Wickens, & Beninger, 1990).
Repeated administration of cocaine, and other
psychostimulants, results in an augmented motor
response known as behavioral sensitization (Kalivas &
Stewart, 1991; Robinson & Becker, 1986).
Sensitization is defined as a progressive increase in
responding to a drug after repeated administration,
whereas tolerance occurs when a drug has a lessened
effect after repeated administration (Kalivas &
Stewart, 1991; Robinson & Becker, 1986). Behavioral
sensitization is thought to reflect processes directly
related to drug craving (Brady, Lydiard, Malcolm, &
Ballenger, 1991; Burger & Martin-Iverson, 1994; Post,
1975; Robinson & Berridge, 1993).
Present treatment options for cocaine addiction
are inadeguate, in that they fail to sufficiently
decrease the intense craving and sensitized responding
that are major components of chronic drug taking
(Robertson, Leslie, & Bennett, 1991; Robinson &
Berridge, 1993). Developing an understanding of
behavioral sensitization and the synaptic changes that
accompany it will be important for developing
5
effective treatments for addiction. Interestingly,
partial D2-like agonists, such as terguride, may have
potential efficacy in the treatment of cocaine
addiction (Pulvirenti & Koob, 1994). For example, it
is possible that partial D2-like agonists may block the
sensitization process by binding to the receptor in
place of dopamine, and thus lessen incessant craving
(Bono, Balducci, Richelmi, Koob, & Pulvirenti, 1996;
Izzo, Orsini, Koob, & Pulvirenti, 2001) . In summary,
empirical studies show that: 1) The dopamine system is
involved in drug addiction; 2) Changes in brain
dopamine levels may be responsible for the addiction
and relapse occurring after repeated psychostimulant
treatment; 3) Behavioral sensitization is an integral
part of the addiction process and results in increased
locomotor activity and stereotypy; and 4) Due to their
pharmacological action on dopamine receptors, partial
D2-like agonists, such as terguride, may have potential
efficacy for the treatment of addiction.
6
CHAPTER TWO
DOPAMINE RECEPTORS
Dopamine is a small catecholamine
neurotransmitter synthesized from tyrosine (for
review, see Cooper et al., 1996). Tyrosine is
converted to L-dihydroxyphenylalanine (L-DOPA) by the
enzymatic activity of tyrosine hydroxylase (TH). L-
DOPA is then converted to dopamine through a rapid
enzymatic process involving amino acid decarboxylase
(Cooper et al., 1996). Dopamine is metabolized in the
cell terminal by monoamine oxidase (MAO) and converted
to dihydroxyphen'ylacetic acid (DOPAC) . In the
synaptic cleft catechol-O-methyltransferase (COMT)
converts dopamine to homovanillic acid (HVA), which is
then processed and excreted from the body (Cooper et
al., 1996)..
Dopamine specific receptors are classified into
the Di-like (Di and D5) arid D2-like (D2, D3, and D4)
family of receptors based on their biochemical,
physiological, and pharmacological actions (see Table
1) (Bouthenet, Souil, Matres, Sokoloff, Giros, &
Schwartz, 1991; Clark & White, 1987).
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Table 1. Dopamine Dj-like and D2-like Receptor 
Properties
Biochemical G- Example
Response Protein Agonist
Example
Antagonist
Di-like Receptor
Di tAdenylyl Cyclase Gs SKF38393 SCH23390
d5 fAdenylyl Cyclase Gs 6-Bromo-APB SCH23390
SCH39166
d2-■like Receptor
d2 jAdenylyl Cyclase Gi quinpirole sulpiride
d3 jAdenylyl Cyclase Gi 7-OH-DPAT AJ-76
Piribedil U99194
d4 j.Adenyly.1 Cyclase G± PD168077 clozapine
L-745,870
Clark and White (1987) confirmed dopamine receptor
selectivity by showing that dopamine agonists and
antagonists have distinct actions on the different
dopamine receptor subtypes. Dopamine receptor
agonists are capable of directly stimulating the
receptor, and frequently have a greater affinity for
the receptor site than the endogenous
8
neurotransmitter. Dopamine receptor antagonists also
bind to the dopamine receptor site, but do not
stimulate the receptor (Cooper et al., 1996). Not
surprisingly, dopamine receptor antagonists attenuate
or reverse dopamine's actions (Cooper et al., 1996).
In all cases, dopamine receptors are metabotropic
G-protein-coupled (guanosine triphosphate GTP-binding
protein) receptors (Cooper et al., 1996). More
specifically, D2-like receptors are coupled to
inhibitory G-proteins (Gi) and, when activated, depress
adenylyl cyclase formation (Baldessarini & Tarazi,
1996) . Di-like receptors are coupled to stimulating G-
proteins (Gs) and, when activated, facilitate adenylyl
cyclase formation (Baldessarini & Tarazi, 1996). In
the latter case, Gs-proteins activate effector proteins
and the resulting adenylyl cyclase converts adenosine
triphosphate (ATP) into cyclic adenosine monophosphate
(cAMP) (Baldessarini & Tarazi, 1996; Hepler & Gilman,
1992; Hille, 1992). The resulting cAMP in the cytosol
activates protein kinase A, causing changes in calcium
and potassium permeability (Beninger & Miller, 1998;
Hepler & Gilman, 1992; Hille, 1992).
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Dopamine receptor subtypes differ in their
affinity for dopamine, as well as for agonist and
antagonist drugs (Cooper et al., 1996; Kebabian &
Caine, 1979; Ujike, Akiyama, & Otsuki, 1990). A major
difference among the Di-like receptor subtypes is that
D5 receptors have a 10-fold higher affinity for
dopamine than Di receptors (Cooper et al., 1996).
Differences in affinity have also been observed within
the D2-like family of receptors. For example, D3
receptors have 70 times greater affinity for dopamine
than Di or D2 receptors (Cooper et al., 1996).
Conversely, D2 receptors have a higher affinity for
apomorphine, a prototypical dopamine agonist drug,
than do D3 or D4 receptors (Cooper et al., 1996).
Other drugs show different receptor binding profiles.
For instance, clozapine (a neuroleptic) has a 10-fold
greater affinity for D4 receptors than D2 or D3
receptors (Gilbert, Millar, & Cooper, 1995). Thus,
the various dopamine receptor subtypes not only have
different affinities for dopamine, they also are
differentially stimulated by dopamine agonist and
antagonist drugs.
10
Due to the role dopamine plays in reward
processes, a substantial number of studies have
examined whether the dopamine neurotransmitter system
is important for addiction. As indicated above, the
functioning of dopamine neurons and receptors can be
altered through pharmacological manipulation. Thus,
therapeutic interventions may eventually be able to
reverse or attenuate some of the psychostimulant-
induced molecular and cellular changes responsible for
addiction.
11
CHAPTER THREE
NEURAL SUBSTRATES OF REWARD
Dopamine neuronal pathways are critical
components of the reward system. Early self­
administration studies by Olds and Milner (1954),
along with work by Dahlstrom and Fuxe (1964), greatly
increased our knowledge regarding reward and
reinforcement. They demonstrated that stimulation of
the medial forebrain bundle, traveling near the
lateral hypothalamus, was rewarding to a subject,
while lesioning the MFB disrupted reward. Additional
studies showed that stimulation of the MFB activates
an endogenous dopamine reward system that projects
from the midbrain to limbic structures (Bozarth,
1991). Subsequent neurochemical stimulation studies
have shown that two major dopamine pathways exist in
brain: the mesolimbic and nigrostriatal pathways (see
Figure 2)(Koob & Bloom, 1988; Wise & Bozarth, 1987).
Both the mesolimbic and nigrostriatal dopamine systems
have unique roles in reward and addiction. The
mesolimbic dopamine pathway is the primary site of
12
Figure 2. Brain Reward Pathways. The mesolimbic 
dopamine pathway originates in the ventral 
tegmentum and extends to the nucleus accumbens. 
Output fibers go to the frontal cortex. The 
nigrostriatal dopamine pathway projects from the 
caudate-putamen. Output fibers go to the frontal 
cortex via the ventral thalamus.
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reward (Wise & Bozarth, 1984). In contrast, the
increased stereotypy observed after chronic
psychostimulant use appears to be due to activation of
the nigrostriatal pathway (Stahl, Ferger, & Kuschinsky,
1997; Wise & Bozarth, 1984). For example,
microinjecting amphetamine into the nucleus accumbens 
results in locomotion and reward (Wise & Bozarth,
1987), whereas, microinjecting amphetamine into the
caudate-putamen results in stereotypy (Arnt, 1987).
Thus, psychostimulants like cocaine enhance
dopaminergic functioning in both the mesolimbic and
nigrostriatal pathways resulting in reward, locomotion,
and stereotypy (Wise & Bozarth, 1984).
The Mesolimbic Dopamine Pathway 
Anatomy and Receptors
The mesolimbic dopamine pathway modulates and
filters signals in the limbic system (Koob, 1992a,
1992b; Pierce & Kalivas, 1997). Efferent neurons from
the ventral tegmental area travel thru the MFB (which
is a major fiber bundle connecting the forebrain to
the midbrain) to the nucleus accumbens (known as the
ventral striatum) (McBride, Murphy, & Ikemoto, 1999;
14
Wise & Bozarth, 1984). Output fibers from the nucleus
accumbens project to the prefrontal cortex (Wise &
Bozarth, 1984). Various brain areas provide
excitatory input into the ventral tegmental area,
including the lateral hypothalamus, prefrontal cortex,
and amygdala (Beninger & Hahn, 1983; Wise & Rompre,
1989; Wise, Spindler, deWit, & Gerber, 1978). The
most important input into the ventral tegmental area
is from the lateral hypothalamus, because it is
critical for the reward associated with food, water,
sex, and predation (Di Chiara, 1999; Leshner & Koob,
1999; Wise & Bozarth, 1984; Wise & Rompre, 1989).
Dopamine Di-like and D2-like receptors are
differentially distributed across brain. Among the Dr
like receptor family, Di receptors are found in high
numbers in the substantia nigra pars reticulata,
caudate-putamen, nucleus accumbens and frontal cortex
(Baldessarini & Tarazi, 1996; Boyson, McGonigle, &
Molinoff, 1986; Dawson, Gehlert, McCabe, Barnett, &
Wamsley, 1986; Mansour, Meador-Woodruff, Bunzow,
Civelli, Akil, & Watson, 1990; Schambra, Duncan,
Breese, Fornaretto, Caron, & Fremeau, 1994). D5
receptors are localized in the cortex, hippocampus and
15
limbic system. Among the D2-like receptor family, D2
receptors are found in high numbers in the caudate-
putamen, striatum, and substantia nigra, while D3
receptors are localized in the olfactory tubercle,
nucleus accumbens, striatum, substantia nigra, and
hypothalamus (Boyson et al., 1986; Dawson et al.,
1986; Mansour et al., 1990; Schambra et al., 1994).
The final member of the D2-like receptor family, the D4
receptor, is found in the frontal cortex, medulla,
hypothalamus, and caudate-putamen (Boyson et al.,
1986; Dawson et al., 1986; Mansour et al., 1990;
Schambra et al., 1994; Tarazi & Baldessarini, 2000).
Although the regional distributions of Di-like and
D2-like receptors have been determined, the functioning
of these receptors has only been partially clarified.
For example, D2-like receptors in the nigrostriatal
pathway appear, to be important for modulating the
intensity of voluntary movement (Baldessarini &
Tarazi, 1996). Di-like receptors have a role in
facilitating the commencement of D2-like activities
(Arnt & Perregaard',- 1987;- Clark & White, 1987) . Di~
like receptors are also thought to be more critical
than D2-like receptors for reward functioning
16
(McDougall et al., 1991, 1992; Miller et al., 1990;
Nakajima, 1986; Nakajima & McKenzie, 1986).
Evidence that Psychostimulant 
Drugs Affect the Mesolimbic
Dopamine Pathway
In both humans and nonhuman animals, stimulation
of the MFB elicits strong feelings of pleasure and
reward (Bozarth, 1991; Koob, 2000; Salamone, Cousins,
& Snyder, 1997). Presumably, these enhanced feelings 
of reward are caused by activation of the nucleus
accumbens via input from the ventral tegmental area
(Bozarth, 1991). The nucleus accumbens is stimulated
not only by natural rewards, such as food and sex, but
also by psychoactive drugs (Di Chiara, 1999; Leshner &
Koob, 1999). In fact, most researchers believe that■ I. \ ,
the nucleus accumbens is the locus where cocaine has
its rewarding actions (Bozarth, 1991).
Substantial amounts of evidence support the idea
that the mesolimbic pathway, and the nucleus accumbens
in particular, is important for cocaine-induced
reward. For example, administering dopamine
antagonists into the nucleus accumbens blocks reward
(Bozarth, 1991; Breiter, Gollub, Weisskoff, Kennedy,
17
Makris, Berke, Goodman, Kantor, Gastfriend, Riorden,
Mathew, Rosen, & Hyman, 1997; Everitt, Parkinson,
Olmstead, Arroyo, Robledo, & Robbins, 1999) .
Conversely, rats will readily self-administer
psychostimulant drugs into the ventral tegmental area
and nucleus accumbens (Schuster & Thompson, 1969).
When electrical stimulation is applied to areas near
the nucleus accumbens, but not in it, there is no
evidence of reward (Bozarth, 1991). Lastly, lesioning
the mesolimbic dopamine pathway fully attenuates self­
administration of both cocaine and amphetamine
(Lyness, Friedle, & Moore, 1979). Therefore, various
types of studies (microinjection, electrical brain
stimulation, and drug self-administration experiments)
suggest that the mesolimbic pathway serves as the
critical substrate for reward (McBride et al., 1999;
Pierce & Kalivas, 1997).
The Nigrostriatal 
Dopamine Pathway
Anatomy and Receptors
The behavioral stereotypy observed after chronic
cocaine exposure is mediated by the nigrostriatal
18
dopamine pathway, which originates in the pars
compacts of the substantia nigra and projects to the
caudate-putamen (also known as the dorsal striatum)
(Arnt & Perregaard, 1987; Pierce & Kalivas, 1997).
Two main output pathways project from the caudate-
putamen: one intrinsic and one extrinsic. The
intrinsic pathway is referred to as the striatonigral
tract, which extends from the caudate-putamen to the
substantia nigra (Gerfen, 1984, 1992). These
descending neurons express Di receptor mRNA and release
both GABA and dynorphin from their terminal fibers
(Gerfen, 1984). The extrinsic pathway projects from
the caudate-putamen to the thalamus and, ultimately,
to premotor areas of the frontal cortex (Gerfen,
1984) .
Evidence that Psychostimulant
Drugs Affect the 
Nigrostriatal Dopamine
Pathway
Various experimental paradigms have shown that
psychostimulant drugs indirectly stimulate the
nigrostriatal dopamine pathway. For example, high
doses of psychostimulant drugs preferentially affect
the nigrostriatal dopamine pathway resulting in
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stereotypy, while lower doses increase locomotor
activity (Asher & Aghajanian, 1974; Kelly, Seviour, &
Iversen, 1975). Using electroencephalograph (EEG)
techniques, Stahl et al. (1997) also found a dose-
dependent effect in which low doses of amphetamine
activated Di-like receptors in the mesolimbic pathway,
while higher doses of amphetamine activated D2-like
receptors in the nigrostriatal pathway. Lastly,
microinjecting amphetamine into the caudate-putamen
and nucleus accumbens produce distinctly different
behavioral profiles. Intense oral stereotypies
develop when amphetamine is microinjected into the
caudate-putamen, while microinjecting amphetamine into
the nucleus accumbens results in locomotion (Dickson,
Lang, Hinton, & Kelley, 1994; Staton & Solomon, 1984).
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CHAPTER FOUR
BEHAVIORAL SENSITIZATION
IN THE ADULT RAT
The enduring behavioral augmentation observed
after chronic cocaine administration is known as
behavioral sensitization (Downs & Eddy, 1932; Robinson
& Becker, 1986).. Behavioral sensitization is
considered to be a major factor in the addiction
process (Bozarth, 1987; Reith et al., 1980; Robinson &
Becker, 1986; Robinson & Berridge, 1993), and is
thought by some to be important for incessant drug
craving and psychostimulant-induced psychoses (Brady
et al., 1991; Post, 1975).
In rodents, enduring locomotor augmentation is
produced by a wide variety of drugs, including
methylphenidate, cocaine, and methamphetamine
(Akimoto, Hamamura, & Otsuki, 1989; Crawford, Drago,
Watson, & Levine, 1997; Crawford, McDougall, Meier,
Collins, & Watson, 1998). In adult rats, cocaine-
induced behavioral sensitization remains evident after
a 3-month abstinence period, while sensitization to
amphetamine and methamphetamine is evident for up to
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12 months (Kalivas & Stewart, 1991; Leith & Kuczenski,
1982; Paulson, Camp, & Robinson, 1991). The strength
of the sensitized response is dependent on multiple
factors, including drug dose, whether the drug is
administered in the home cage or a novel environment,
and drug pre-exposure schedule (McDougall, Collins,
Karper, Watson, & •. Crawford, 1999; Robinson & Berridge,
1993; Snyder, Katovic, & Spear, 1998; Weiss, Post,
Pert, Woodward, & Murman, 1989; Zavala, Nazarian,
Crawford, & McDougall, 2000).
The neural mechanisms underlying behavioral
sensitization are only partially understood. For
example, some researchers have shown that drug-induced
changes in the Di-like receptor are probably
responsible for the plasticity associated with
behavioral sensitization (Henry & White, 1991, 1995;
Kalivas, 1995; Vezina, 1996). Other researchers have
posited that D2-like autoreceptor supersensitivity in
the ventral tegmental area is responsible for the
enhanced synaptic dopamine levels occurring in
behavioral sensitization (Wolf, White, Nassar,
Brooderson, & Khansa, 1993). With continued research
it is anticipated that the precise mechanisms
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mediating behavioral sensitization will become fully
elucidated.
Induction and Expression of 
Behavioral Sensitization
Induction
Behavioral sensitization can be divided into two
distinct processes referred to as induction (also
known as development or initiation) and expression
(Kalivas & Stewart, 1991; Leith & Kuczenski, 1982;
Pierce & Kalivas, 1997; Robinson & Becker, 1986;
Vanderschuren & Kalivas, 2000). Induction is the
process by which a subject initially develops a
sensitized response. Induction is characterized by a
progressive day-dependent increase in behavioral
responding that occurs after repeated administration
of a psychostimulant drug. It is likely that
induction is the result of long-lasting cellular 
changes in the neuron caused by chronic
psychostimulant exposure (Pierce & Kalivas, 1997).
Specifically, induction is correlated with blockade of
the dopamine reuptake pump, an increase in dopamine
levels in the synapse, and a decrease in D2-like
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autoreceptor sensitivity (Henry & White, 1991; Kalivas
& Stewart, 1991; Pierce & Kalivas, 1997; Robinson &
Becker,* 1986; Vezina, 1996; Vezina & Stewart, 1989;
Wolf, 1998).
Recent empirical evidence has more fully
elucidated the neuronal mechanisms important for
induction of behavioral sensitization. Repeated
administration of amphetamine into the ventral
tegmental area, but not the nucleus accumbens, causes
a sensitized response after subsequent drug challenge
(Kalivas & Duffy, 1990). This finding suggests that
the ventral tegmental area is the primary site
responsible for the induction of behavioral
sensitization. Wolf, White, and Hu (1994) reported
that the neurochemical changes observed in the ventral
tegmental area are transient and occur soon after
initial drug exposure. Changes in the nucleus
accumbens are longer lasting and require substantially
more drug exposures (Wolf et al., 1993, 1994). Thus,
these results suggest that psychostimulant-induced
changes in the ventral tegmental area are probably
responsible for the induction of behavioral
24
sensitization, whereas changes in the nucleus
accumbens are more clearly associated with expression.
Expression
Expression of behavioral sensitization occurs
when a subject previously exposed to a psychostimulant
shows an enhanced behavioral response after acute drug
challenge (Henry & White, 1991; Pierce & Kalivas,
1997) . The nucleus accumbens is important for the
expression of behavioral sensitization (Pierce &
Kalivas, 1997; Vanderschuren & Kalivas, 2000; Wolf,
1998) . Long-term expression of behavioral
sensitization is thought by some to be a result of Di-
like receptor supersensitivity in the axon terminals
of the nucleus accumbens and striatum (Henry & White,
1991; Wolf, 1998). Consistent with this idea, Di-like
receptor' antagonists block expression of behavioral
sensitization, even though the induction of behavioral
sensitization had previously occurred (Mattingly,
Hart, Lim, & Perkins, 1994; White, Joshi, Koeltzow, &
Hu, 1998) .
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Associative Learning in 
Behavioral Sensitization
Empirical evidence indicates that the overall
strength of the .sensitized response is increased when
Pavlovian associations are formed between the
environment and the drug (Badiani, Brownian, &
Robinson, 1995). In this situation, the effect drug's
neurochemical actions function as the unconditioned
stimulus (US), while the environment and the locomotor
activity are the conditioned stimulus (CS) and
unconditioned response (UR), respectively (Campbell &
Raskin, 1978). For this reason, a novel environment
has been shown to facilitate the development of
behavioral sensitization to cocaine, amphetamine, and
other psychostimulants (Badiani et al., 1995;
Shippenberg et al., 1996; Tirelli & Terry, 1998).
Thus, sensitized responding is more robust when
cocaine challenge occurs in the same environment where
the subject initially received the drug (Badiani et
al., 1995; Shippenberg et al., 1996; Tirelli & Terry,
1998).
Behavioral sensitization may be an important
component in drug craving. During behavioral
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sensitization, the environment takes on cue salience
and is able to produce craving on its own (Burger &
Martin-Iverson, 1994; Post, Weiss, & Pert, 1992;
Robinson & Becker, 1986; Tirelli, 2001). Consistent
with this idea, rats spend more time in an environment
that has been paired with a psychostimulant drug
(Crombag, Badiani, Chan, Dell'Oreo, Dineen, &
Robinson, 2001). Interestingly, rats exhibit
increased brain dopamine levels when they are placed
in a previously drug-paired environment even if no new
drug is administered (Crombag et al., 2001; Rebec,
Grabner, Johnson, Pierce, & Bardo, 1997).
The relationship between drug and environment may
be relevant to the issue of drug relapse in humans.
More specifically, exposure to the drug-taking
environment can result in drug relapse (Wise, 1988).
This finding was first reported over 50 years ago, as
Wikler (1948) noted that post-detoxification patients
returning to their old environments experienced drug
craving and relapse. The reinstatement of desire for
a drug can occur after months, or even years, of drug
abstinence (National Institute of Drug Abuse, 1999;
Wise, 1988). It has even been estimated that 45% of
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drug relapse may be due to associative processes
involving the pairing of drug cues with environmental
factors (Wise, 1988). Thus, there is substantial
evidence supporting the argument that environmental
cues are a critical factor in the addiction process.
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CHAPTER FIVE
ONTOGENY OF BEHAVIORAL
SENSITIZATION
Psychostimulant-induced behavioral sensitization
shows ontogenic changes from the preweanling period to
adulthood (Fujiwara, Kazahaya, Nakashima, Sato, &
Otsuki, 1987; McDougall, Duke, Bolanos, & Crawford,
1994; Wood, Tirelli, Snyder, Heyser, LaRocca, & Spear,
1998; Zavala et al., 2000). Early studies using
cocaine and amphetamine suggested that young animals
were incapable of showing behavioral sensitization
after repeated psychostimulant treatment (Barr & Wang,
1993; Fujiwara et al., 1987; Kolta, Scalzo, Ali, &
Holson, 1990; Tsuchida, Ujike, Kanzaki, Fujiwara, &
Akiyama, 1994). More recent studies report that
behavioral sensitization to psychostimulant drugs is
attainable in the young rat, although it is not as
robust as in adults (Duke, O'Neal, & McDougall, 1997;
McDougall et al., 1994; Tirelli & Ferrara, 1997; Wood
et al., 1998; Zavala et al., 2000). A possible
explanation for these age-dependent behavioral
differences is that dopamine receptor systems may be
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functionally immature in the young animal (Fujiwara et
al., 1987; McDougall et al., 1994; Ujike, Tsuchida,
Akiyama, Fujiwara, & Kuroda, 1995; Wood et al., 1998).
Thus, as the dopamine system matures, sensitized
responding may become more robust. Another
explanation is that young and adult rats may differ in
how readily they form Pavlovian associations between
the environmental context and the drug (Wood et al.,
1998; Zavala et al., 2000). Since Pavlovian
associations are critical for the expression of
behavioral sensitization, an inability to form such
associations would negatively impact the robustness of
the sensitized response.
A number of ontogenic constraints affect the
induction and expression of behavioral sensitization,
including the number of pre-exposure days and the
length of the drug abstinence period. For example, as 
little as one drug pre-exposure is capable of inducing
behavioral sensitization in adult rats, and the
sensitized response may be detected for many months
(Fontana, Post, Weiss, & Pert, 1993; Leith &
Kuczenski, 1982; Paulson et al. , 1991; Weiss et al.,
1989) . In order to elicit cocaine-induced behavioral
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sensitization in preweanling rat pups, a longer pre­
exposure phase and a shorter drug abstinence period is
required (McDougall et al., 1994; Tirelli & Ferrara,
1997; Zavala et al.,'2000). For example, Zavala et
al. (2000) found that 10 drug pre-exposure days,
rather than the usual 5 days, was necessary to produce
a sensitized response that persisted across seven drug
abstinence days. Further, Snyder et al. (1998)
obtained a sensitized locomotor response to cocaine
after a 21-day drug abstinence period, but only if an
extended pre-exposure phase was used. This shows that
the number of pre-exposure days, and the length of the
drug abstinence period, are a critical constraint
affecting the occurrence of behavioral sensitization
(Zavala et al., 2000).
As mentioned above, ontogenic differences in
behavioral sensitization may be due to maturational
changes in the dopamine system (Fujiwara et al., 1987;
McDougall et al., 1994; Ujike et al., 1995; Wood et
al., 1998). For example, certain components of the
dopamine system, including reuptake pumps and
receptors, show substantial changes across the
preweanling period (Arnauld, Arsaut, Tafani, &
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Demotes-Mainard, 1995; Gelba.rd, Teicher, Faedda, &
Baldessarini, 1989; Giorgi, De Montis, Porceddu, Mele,
Calderini, Toffano, & Biggio, 1987; Pardo, Creese,
Burt, & Snyder, 1977). Immaturity of the dopamine
system has functional consequences, as the mesolimbic
and nigrostriatal dopamine pathways appear to be
hypoactive in younger animals (Arnauld et al., 1995;
Pardo et al.,1977).
Another explanation for the ontogenic changes in
behavioral sensitization may involve age-dependent
differences in the ability to form and maintain
Pavlovian associations (Zavala et al., 2000). For
example, Zavala et al. (2000) found that sensitization
was not dependent on associative factors when drug
challenge occurred after only one abstinence day
(i.e., a sensitized response was observed when the
pre-exposure drug was given in the home cage rather
than the test chamber). However, when a seven-day
drug abstinence period was employed, rat pups only
exhibited a sensitized response if drug pre-exposure
and challenge occurred in the same previously novel
environment (Zavala et al., 2000). When considered
together, these findings show that Pavlovian factors
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are particularly important for the occurrence of
behavioral sensitization in preweanling rats. It is
conceivable that young rats may have more difficulty
forming the necessary associations between the
psychostimulant drug and the environmental context,
thus requiring an extended pre-exposure phase for the
association to take place (Zavala et al., 2000).
In summary, empirical evidence shows that: 1) The
sensitization process is dependent on changes across
ontogeny; 2) Young rats can exhibit behavioral
sensitization to psychostimulant drugs, although the
sensitization is not as robust as that observed in
adult rats; 3) The number of pre-exposure days and the
length of the drug abstinence period are important
ontogenic constraints affecting the occurrence of
behavioral sensitization; 4) Ontogenic. differences in
behavioral sensitization may be due to (a)
maturational changes in the dopamine system or (b)
age-dependent differences in the ability to form
Pavlovian associations between the drug and
environmental context.
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CHAPTER SIX
PHARMACOLOGICAL ACTION OF
PARTIAL D2-LIKE RECEPTOR
AGONISTS
Although psychostimulant addiction is a major
problem in society, no effective pharmacotherapies
have yet been developed to treat this problem
(National Institute of Drug Abuse, 1999). Dopamine
receptor antagonists are effective at blocking reward,
but complete blockade of dopamine receptors produces
anhedonia and motor side effects (e.g., tardive
dyskinesia and tremors) (for reviews, see
Baldessarini, 1996; Miller et al., 1990). Partial D2-
like receptor agonists have been suggested as a
potential pharmacotherapy that may be effective in
reducing the rewarding value of psychostimulant drugs,
without having the same aversive properties as
dopamine receptor antagonists.
Partial D2-like receptor agonists have both
agonist and antagonist actions on G-protein-coupled
dopamine receptor sites (Hoyer- & Boddeke, 1993). In
situations where dopaminergic functioning is
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depressed, partial D2-like agonists act in an agonistic
manner, thus stimulating the dopamine system. In
situations where dopaminergic functioning is enhanced,
partial D2-like agonists act in an antagonistic manner,
thus depressing the dopamine system (Clark, Furmidge,
Petry, Tong, Ericcson, & Johnson, 1991) . Because
partial D2-like agonists bind to dopamine receptor
sites with high affinity and low intrinsic activity,
this class of drugs has the ability to block the
effects of psychostimulant drugs without depressing
baseline levels of dopaminergic activity (Hoyer &
Boddeke, 1993) .
Pre- and postsynaptic D2-like receptors are
differentially affected by partial D2-like receptor
agonists. For example, D2 autoreceptors are 5-10 times
more sensitive to partial agonist activity than D2-like
postsynaptic receptors (Clark & White, 1987).
Although exhibiting low intrinsic affinity for D2-like
postsynaptic receptors, partial D2-like agonists
typically have antagonistic actions at these receptor
sites (Arnt et al., 1987; et al., 1991; Clark, Salah,
& Galloway, 1991). In the nucleus accumbens, cocaine
enhances dopaminergic activity by indirectly
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stimulating postsynaptic D2-like receptors. Thus,
functioning of the mesolimbic pathway could
potentially be restored to normal levels if cocaine's
actions were attenuated by a partial D2-like agonist
(Izzo et al., 2001; Robertson et al., 1991).
Terguride, an analog of lisuride is a partial D2-
like dopamine receptor agonist that has
pharmacological properties suggesting potential
efficacy in the treatment of addiction (Briicke,
Bankiewicz, Harvey-White, & Kopin, 1988; Carratu,
DeSerio, Mitolo-Chieppa, & Federico, 1991; Ekman &
Eriksson, 1992; Koller & Herbster, 1987; Lange,
Loschmann, Wachtel, Horowski, Jahnig, Jenner, &
Marsden, 1992; Piercy, Hoffman, Vogelsang, & Travis,
1987). D2-like agonists, such as terguride, may be
able to modulate multiple aspects of psychostimulant
addiction. For example, .terguride decreases both
cocaine self-administration (Clark, Furmidge, et al.,
1991; Clark, Salah, et al., 1991; Pulvirenti,
Balducci, Piercy, & Koob, 1998; Spealman, 1995) and
alcohol consumption in rats (Bono et al., 1996). This
seems to indicate that terguride has a modulating
effect on craving, perhaps by normalizing dopaminergic
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functioning in the nucleus accumbens. Terguride also
blocks cocaine-induced locomotor activity, suggesting
that this partial D2-like agonist is capable of
attenuating other reward-related behavioral effects
(Clark, Furmidge, et al., 1991). Lastly, terguride
alone is not rewarding (Callahan & Cunningham, 1993; 
Pierce & Kalivas, 1997), nor does it possess the
discriminative stimulus properties of other
psychostimulants (Akai, Ozawa, Yamaguchi, Mizuta, &
Kuno, 1995; Akai, Yamaguchi, Mizuta, & Kuno, 1993;
Callahan & Cunningham, 1993; Pierce & Kalivas, 1997) .
The latter point is important, because drugs that act
as discriminative stimuli can produce cue-induced 
craving (Akai et al., 1995; Callahan & Cunningham,
1993; Pierce & Kalivas, 1997).
In summary, the potential efficacy of partial D2-
like receptor agonists, such as terguride, may lie in 
their ability to modulate critical processes involving
psychostimulant addiction (i.e., reward and incessant
craving) (Bono et al., 1996; Brucke et al., 1988; Izzo
et al. , 2001; Pulvirenti & Koob, 1994; Ranaldi, Wang,
& Woolverton, 2001; White et al., 1998). As shown in
the above studies, substantial evidence suggests that
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terguride may have therapeutic benefits for
psychostimulant addiction.
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CHAPTER SEVEN
PURPOSE
In general, the contents of the previous chapters
can be summarized as follows: 1) Endogenous activation
of dopamine receptors in the mesolimbic pathway is
rewarding; 2) Cocaine exogenously activates the
mesolimbic pathway, not only causing reward, but also
producing long-term changes in neurotransmitter
functioning; 3) Behavioral sensitization is believed
to be a critical component of the addiction process;
4) Psychostimulant-induced behavioral sensitization
shows ontogenic changes (i.e., the sensitized
responding of preweanling rats is not as robust as
that shown by adults); 5) If the dopamine system is
maximally activated, partial D2-like agonists have the
ability to depress dopaminergic functioning.towards
basal levels. It has already been established that
partial D2-like agonists can reduce the rewarding
effects of cocaine and other psychostimulants (Bono et
al., 1996; Izzo et al., 2001; Pulvirenti et al.,
1998). It is unclear, however, whether partial D2-like
agonists can block the induction and-expression of
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behavioral sensitization. If partial D2-like agonists
are capable of blocking behavioral sensitization, it
would provide additional evidence that this class of
drugs might have therapeutic efficacy for the
treatment of psychostimulant addiction.
Based on previous findings, it was hypothesized
that a partial D2-like agonist (i.e., terguride) would
block both the induction and expression of behavioral
sensitization in preweanling rats. It was further
hypothesized that terguride would not produce
behavioral sensitization by itself. To test these
hypotheses I conducted four experiments. In
Experiments 1 and 2, I investigated whether terguride
would block induction of cocaine-induced behavioral
sensitization in preweanling rats. In Experiment 3, I
examined whether a test day injection of terguride
would block expression of cocaine-induced behavioral
sensitization. In Experiment 4, the focus was to
determine whether terguride itself can produce
behavioral sensitization. If terguride produces
behavioral sensitization, it would suggest that this
partial D2-like agonist has abuse potential in its own
right.
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CHAPTER EIGHT
GENERAL METHODS
Subjects
Subjects were 242 (n = 8 per group) male and
female rat pups of Sprague-Dawley descent (Charles
River, Wilmington, MA), born and raised at California
State University, San Bernardino. Litters were culled
to ten pups by 3 days of age and kept with the dam
throughout behavioral testing. Assignment of males
and females to groups was random, with only one rat
per litter in each particular group. Rats were housed
in the colony room on a 12:12 hr light-dark cycle.
Temperature was maintained at 22-24°C. Behavioral
testing was done during the light cycle, at
approximately the same time each day. Subjects were
treated according to the American Psychological
Association "Ethical Principles" (1992), and the
Principles of Laboratory Animal Care (National
Institute of Health Publication # 85-23).
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Apparatus
Coulbourn Tru-Scan (Coulbourn Instruments,
Allentown, PA) activity monitoring chambers (25.5 x
25.5 x 41 cm) were used to measure distance traveled
(i.e., horizontal locomotor activity). The Coulbourn
chambers have clear Plexiglas walls, open tops, and
smooth plastic floors. Each chamber has 16 photocells
and detectors in an X-Y photobeam arrangement. To
avoid olfactory contamination the Plexiglas walls were
wiped with 30% alcohol between subjects. The floor
trays were cleaned with a commercially available
bactericide between testing sessions.
.Drugs
Terguride (transdihydrolisuride) (Sigma, St
Louis, Mo) was dissolved in a drop of glacial acetic
acid and then mixed in saline. Cocaine (Sigma) was
dissolved in saline. All injections were given
intraperitoneally (i.p.) at a volume of 5 ml/kg.
Statistical Analysis
Behavioral data were analyzed using repeated
measures analyses of variance (ANOVA). Distance
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traveled was the dependent variable in all
experiments. In each of these analyses, litter
effects were controlled by using within-litter
statistical procedures (Zorrilla, 1997). Additional
analysis of behavioral data was made using Tukey
tests. Alpha level criterion of .05 was used for all
ANOVA's and Tukey tests.
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CHAPTER NINE
.EXPERIMENT ONE
The purpose of this experiment was to assess
whether low doses of terguride (0.1-0.4 mg/kg) are
capable of blocking the induction of behavioral
sensitization to cocaine.
Procedure
Pre-Exposure Phase (Days 1-7)
• The pre-exposure phase started at postnatal PD 15
and continued to PD 21. On. seven consecutive days
I(i.e., PD 15-21), pups were injected with saline or.
I
terguride (0.1, 0.2, or 0.4 mg/kg). Pups were then
returned to the dam in their home cage. After 30 min,
pups were taken to the experimental room and placed in
individual chambers for a 5-min habituation period.
At the end of habituation, pups initially injected
with saline'were injected with either cocaine (30
mg/kg) or saline. In contrast, pups initially
injected with terguride were injected with cocaine (30 
mg/kg). After the 30-min observation session, pups
were returned to the dam in, their home cage. In 
summary, five groups of rais received the following
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5-min time blocks) repeated measures ANOVA. Post hoc
analysis of behavioral data 'was made using Tukey
tests.
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CHAPTER TEN
EXPERIMENT TWO
The purpose of this experiment was to assess
whether higher doses of terguride (0.4-1.6 mg/kg) are
able to block the induction of behavioral
sensitization to cocaine.
Procedure
Pre-Exposure Phase (Days 1-7)
The pre-exposure phase started at PD 15 and
continued to PD 21. On seven consecutive days (i.e.,
PD 15-21), pups were injected with saline or terguride
(0.4, 0.8, or 1.6 mg/kg). Pups were then returned to
the dam in their home cage. After 30 min, pups were
taken to the experimental room and placed in
individual chambers for a 5-min habituation period.
At the end of habituation, half of the pups were
injected with cocaine (30 mg/kg) and the other half
received saline. After the 30-min observation
session, pups were returned to their home cage. In
summary, eight groups of rats received the following
sequence of drugs on each day of the pre-exposure
phase: Sal-Sal, Terg(0.4)-Sal, Terg(0.8)-Sal,
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Terg(1.6)-Sal, Sal-Coe, Terg(0.4)-Coc, Terg(0.8)-Coc,
and Terg(1.6)-Coc. As mentioned above, the initial
injection of saline or terguride occurred 30 min prior
to the cocaine injection.
Test Day (Day 9)
After a 24 h drug abstinence period,
sensitization was assessed on a single test day. On
the test day (PD 23), pups were injected with saline
and returned to the dam for 30 min. Pups were then
taken to the experimental room and placed in a chamber
for a 5-min habituation period. After habituation,
all pups were given a single challenge injection of
cocaine (15 mg/kg). After the 30-min testing period,
pups were returned to their home cage.
Statistical Analysis
Horizontal locomotor activity during the pre­
exposure phase was analyzed using a 4 x 2 x 7 (Pre-
Exposure Drug x Stimulant Condition x Pre-Exposure Day)
repeated measures ANOVA; whereas, horizontal locomotor
activity from test day was analyzed using a 4 x 2 x 6
(Pre-Exposure Drug x Stimulant Condition x 5-min time
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blocks) repeated measures ANOVA. Post hoc analysis of
behavioral data was made using Tukey tests.
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CHAPTER ELEVEN
EXPERIMENT THREE
The purpose of this experiment was to assess
whether terguride is capable of blocking the
expression of behavioral sensitization to cocaine.
Procedure
Pre-Exposure Phase (Days 1-7)
The pre-exposure phase started at PD 15 and
continued to PD 21. On seven consecutive days (i.e.,
PD 15-21), pups were taken to the experimental room
and placed into the individual chambers for a 5-min
habituation period. At the end of habituation, half
of the pups were injected with cocaine (30 mg/kg) and
the other half with saline. After the 30-min
observation session, pups were returned to their home
cage.
Test Day (Day 9)
After a 24 h drug abstinence period,
sensitization was assessed on a single test day. On
the test day (PD 23), pups were injected with saline
or terguride (0.2, 0.4, or 0.8 mg/kg) and returned to
50
their home cage for 30 min. After 30 min, pups were
taken to the testing room and placed in a chamber for
a 5-min habituation period. At the end of
habituation, pups were injected with a challenge dose
of cocaine (15 mg/kg). After the 30-min testing
period, pups were returned to their home cage. As
mentioned above, the initial dose of saline or
terguride occurred 30 min prior to -the cocaine
inj ection.
Statistical Analysis
Horizontal locomotor activity from the pre­
exposure phase was analyzed using a 2 x 7 (Stimulant
Condition x Pre-Exposure Day) repeated measures ANOVA
whereas, horizontal locomotor activity from test day
was analyzed using a 2 x 4 x 9 (Stimulant Condition x
Test Day Drug x 5-min time blocks) repeated measures
ANOVA. Post hoc analysis of behavioral data was made
using Tukey tests.
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CHAPTER TWELVE
EXPERIMENT FOUR
The purpose of this experiment was to assess
whether terguride is capable of producing behavioral
sensitization.
Procedure
Pre-Exposure Phase (Days 1-7)
The pre-exposure phase started at and continued
to PD 21. On seven consecutive days (i.e., PD 15-21),
pups were taken to the experimental room and placed
into individual chambers for a 5-min habituation
period. At the, end of habituation, all pups were
injected with saline or terguride (0.4, 0.8, or 1.6 
mg/kg). After the 60-min observation session, pups 
were returned to their home cage.
Test Day (Day 9)
After a 24 h abstinence period, sensitization was
assessed on a single test day. On the test day (PD
23), pups were taken to the testing room and placed in
a chamber for a 5-min habituation period. After
habituation, pups were given a challenge injection of 
either saline or terguride (0.4 mg/kg). After the 60-
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min testing period, pups were returned to their home
cage.
Statistical Analysis
Horizontal locomotor activity during the pre­
exposure phase was analyzed using a 4 x 7 (Drug
Condition x Pre-Exposure Day) repeated measures ANOVA;
whereas, horizontal locomotor activity from test day
was analyzed using a 4 x 12 (Drug Condition x Test Day
Drug x 5-min time blocks) repeated measures ANOVA.
Post hoc analysis of behavioral data was made using
Tukey tests.
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CHAPTER THIRTEEN
RESULTS
Experiment One
Pre-Exposure Phase
Overall, rats showed a day-dependent increase in
distance traveled (i.e., horizontal locomotor
activity) across the pre-exposure phase [Pre-Exposure
Day main effect, F(6,54) = 27.36, p < .05] (see Figure
3). This effect varied according to drug group, as
rats receiving cocaine (filled symbols) exhibited
greater horizontal locomotor activity than saline
controls (open symbols) [Stimulant Condition main
effect, F(4,36) = 12.53, p < .05]. Tukey tests
revealed that only rats in the 0.0 mg/kg Terg/Coc
groups had greater horizontal locomotor activity than
saline controls on PD 16;- whereas, on PD 17, rats in
the 0.0 mg/kg Terg/Coc and 0.2 mg/kg Terg/Coc groups 
exhibited more locomotor activity than rats in the 0.0
mg/kg Terg/Sal group [Stimulant Condition x Pre-
Exposure Day interaction, F(24,216) = 4.43, p < .05]. 
By PD 18, only rats in the 0.4 mg/kg Terg/Coc group
did not exhibit more distance traveled than saline
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14,000
Pre-Exposure Phase
Figure 3. Mean (+ SEM) distance traveled (i.e., 
locomotor activity) of rats (n = 8 per group) given 
daily injections of terguride (0.0, 0.1, 0.2, or 0.4 
mg/kg, i.p.) followed, 35 min later, by an injection 
of saline (open circles) or 30 mg/kg cocaine (filled 
symbols). Behavioral testing lasted 30 min.
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controls. On.the final three days of the pre-exposure
phase (i.e., on PD 19-21), all of the groups treated
with cocaine had greater horizontal locomotor activity
than saline controls.
A separate ANOVA was conducted to determine
whether the various cocaine groups differed among
themselves. This analysis showed that rats receiving
both terguride and cocaine had significantly less
horizontal locomotor activity than rats receiving
cocaine alone [Stimulant Condition main effect,
F(3,27) = 3.48, p < .05] (see Figure 4). Tukey tests
revealed a significant decrease in cocaine-induced
locomotor activity in all Terg/Coc Groups (0.1-0.4
mg/kg). The ability of terguride to reduce cocaine- 
induced locomotor activity did not vary according to
pre-exposure day. Therefore, these results indicate
that low doses of terguride partially attenuate the
locomotor activating effects of cocaine.
Test Day
Overall, cocaine induced a sensitized locomotor
response, since rats in the 0.0 mg/kg Terg/Coc group
(filled circles) had greater horizontal locomotor
56
Pre-Exposure Phase
Terguride (mg/kg)
Figure 4. Mean (+ SEM) distance traveled (i.e., 
locomotor activity) of rats (n = 8 per group) given 
daily injections of terguride (0.0, 0.1, 0.2, or 0.4 
mg/kg, i.p.) followed, 35 min later, by an injection 
of 30 mg/kg cocaine (these are the same rats as 
described in Fig. 3). Data are collapsed across the 
pre-exposure phase. *Significantly different from
rats receiving 0.0 mg/kg terguride.
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activity than the rats in the 0.0 mg/kg Terg/Sal group
(open circles) on time blocks 1, 2, and 5 [Stimulant
Condition x Time interaction, F(5,45) = 6.55 p < .05]
(see Figure 5). An ANOVA including all five treatment
groups showed that horizontal locomotor activity
varied across the testing session, with rats in the
cocaine groups (filled symbols) exhibiting more test
day locomotion than.rats treated with saline during
the pre-exposure phase (open circles) [Stimulant
Condition x Time interaction, F(20,180) = 2.45, p <
.05]. Importantly, however, terguride (0.1-0.4 mg/kg)
did not reduce the horizontal locomotor activity of
cocaine-pretreated rats (compare the filled symbols).
Thus, there is no evidence that low doses of terguride 
(0.1-0.4 mg/kg) administered during the pre-exposure 
phase block the induction or eventual expression, of
cocaine-induced locomotor sensitization.
Experiment Two
Pre-Exposure Phase
Overall, cocaine-treated rats had greater
horizontal locomotor activity than saline-treated rats
[Stimulant Condition main effect, F(l,7) = 86.49, p <
58
Test Day
5,000-
UJ 4,000-
CO4j,
1 3,000-
2,000-
<D
CD 
O 
c 
(C
w 1,000-
-O’ 0.0 mg/kg Terg/Saline 
-•-0.0 mg/kg Terg/Cocaine 
-♦-0.1 mg/kg Terg/Cocaine 
-Jr- 0.2 mg/kg Terg/Cocaine 
-■- 0.4 mg/kg Terg/Cocaine
—|— 
2
-i-
53 4
5-Min Time Blocks
Figure 5. Mean (+ SEM) distance traveled (i.e., 
locomotor activity) of rats (n = 8 per group) 
receiving a challenge injection of 15 mg/kg cocaine 
after one drug abstinence day (i.e., PD 23). During 
the pre-exposure phase, rats had received daily 
injections of terguride (0.0, 0.1, 0.2, or 0.4 mg/kg, 
i.p.) followed, 35 min later, by an injection of 
saline (open circles) or 30 mg/kg cocaine (these are 
the same rats as described in Figs. 3 & 4). Behavioral 
testing lasted 30 min.
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.05] (see Figure 6). Horizontal locomotor activity of
rats increased in a day- dependent manner over the
pre-exposure phase [Pre-Exposure Day main effect,
F(6,42) = 14.78, p < .05] (see Figure 6); however,
this effect varied according to both pre-exposure drug
and stimulant condition [Pre-Exposure Drug x Stimulant
Condition x Pre-Exposure Day interaction, F(18,126) =
3.40, p < .05]. Horizontal locomotor activity of
saline-treated rats was reduced by terguride (see
upper graph, Figure 6), as Tukey tests showed that
rats in the 0.0 mg/kg Terg/Sal group (open circles)
exhibited more horizontal locomotor activity on PD 15
and PD 17 than rats in the 0.4-1.6 mg/kg Terg/Sal
groups (other open symbols). On PD 18, rats in the
0.0 mg/kg Terg/Sal group had more horizontal locomotor 
activity than rats in the 0.8 mg/kg and 1.6 mg/kg 
Terg/Sal groups.
A different pattern of results was observed with
cocaine-treated rats (see lower graph, Figure 6).
Across the pre-exposure phase rats in the 0.0 mg/kg
Terg/Coc group (filled circle) had more horizontal 
locomotor activity than all other Terg/Coc groups
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Figure 6. Mean (+ SEM) distance traveled (i.e., 
locomotor activity) of rats (n = 8 per group) given 
daily injections ofterguride (0.4, 0.8, or 1.6 mg/kg, 
i.p.) followed, 35 min later, by an injection of 
saline (open symbols) or 30 mg/kg cocaine (filled 
symbols). Behavioral testing lasted 30 min.
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(other filled symbols). The only exception was on PD
19, when no group differences were apparent.
Generally, rats pretreated with the various doses of
terguride (0.4-1.6 mg/kg) behaved similarly, but on PD
18, rats in the 0.4 mg/kg Terg/Coc group had greater
locomotor activity than rats in the 0.8 mg/kg and 1.6
mg/kg Terg/Coc groups.
Test Day
Overall, cocaine induced a sensitized locomotor
response, as rats pre-exposed to cocaine had greater
horizontal locomotor activity than saline pre-exposed
rats on time blocks 1-5 [Stimulant Condition x Time
interaction, F(15,105) = 6.14, p < .05] (see Figure
7). Administering terguride during the pre-exposure
phase did not affect subsequent responding on the test
day. Specifically,' terguride did not reduce the
cocaine-induced horizontal locomotor activity of
either the saline pre-exposed rats (see upper graph,
Figure 7), or the cocaine pre-exposed rats (see lower
graph, Figure 7).
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Figure 7. Mean (+ SEM) distance traveled of rats (n =
8 per group) receiving a challenge injection of 15 
mg/kg cocaine after one drug abstinence day (i.e., PD 
23). During the pre-exposure phase, rats had received 
daily injections of terguride (0.0, 0.4, 0.8, or 1.6 
mg/kg, i.p.) followed, 35 min later, by an injection 
of saline (open symbols) or 30 mg/kg cocaine (filled 
symbols (these are the same rats as described in Fig.
6). Behavioral testing lasted 30 min.
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Experiment Three
Pre-Exposure Phase
Overall, rats treated with cocaine (filled
circles) exhibited greater distance traveled (i.e.,
horizontal,locomotor activity) than rats treated with
saline (open circles) [Stimulant Condition main
effect, F(l,7) = 195.89, p < .05] (see Figure 8).
This effect varied according to pre-exposure day, as
cocaine-treated rats exhibited a day-dependent
increase in horizontal locomotor activity across the
pre-exposure phase [Pre-Exposure. Day main effect,
F(6,42) = 8.27, p < .05; Stimulant Condition x Pre-
Exposure Day interaction, F(6,42) = 20.93, p < .05]
(see Figure 8).
Test Day
As expected, a separate ANOVA comparing the
saline- and cocaine-pretreated rats showed that
repeated treatment with cocaine produced behavioral
sensitization (see Figure 9). An overall ANOVA
comparing all groups showed that horizontal locomotor
activity of the saline- and cocaine-pretreated rats
differed [Stimulant Condition main effect, F(l,7) =
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Figure 8. Mean (+ SEM) distance traveled (i.e., 
locomotor activity) of rats (n = 32 per group) 
receiving daily injections of saline (open symbols) or 
30 mg/kg cocaine (filled symbols). Behavioral testing 
lasted 30 min.
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Figure 9. Mean (+ SEM) distance traveled of rats (n =
8 per group) receiving a challenge injection of 15 
mg/kg cocaine on the test day. Rats had received a 
test day injection of 0.0 mg/kg terguride 35 min prior 
to cocaine treatment. During the pre-exposure phase, 
rats had received daily injections of saline (open 
circles) or 30 mg/kg cocaine (filled circles). 
Behavioral testing lasted 45 min.
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17.80; Stimulant Condition x Time interaction, F(8,56)
= 2.64, p < .05] (see Figure 10). Among the saline-
pretreated groups (see upper graph, Figure 10), rats
receiving both cocaine and 0.0 mg/kg terguride (open
circles) had greater horizontal locomotor activity
than those receiving cocaine and 0.2-0.8 mg/kg
terguride (other open symbols) [Test Day Drug main
effect, F(3,21) = 5.03, p < .05]. The differences
between the 0.0 mg/kg terguride group and the 0.2-0.8
mg/kg groups reached statistical significance on time
blocks 1-3 [Test Day Drug x Time interaction, F(24,168)
= 5.96, p < .05]. Thus, terguride significantly
reduced the cocaine-induced locomotor activity of rats
that had been previously treated with saline during
the pre-exposure phase.
A similar pattern of results was observed in the
cocaine-pretreated rats (see lower graph, Figure 10).
On time blocks 2 and 3, cocaine-treated rats in the
0.0 mg/kg Terg/Coc group (filled circles) exhibited 
more locomotor activity than rats the 0.4 mg/kg and 
0.8 mg/kg Terg/Coc groups (filled triangle and filled 
square, respectively). During time block 4, the 0.0
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Figure 10. Mean (+ SEM) distance traveled of rats (n = 
8 per group) receiving a challenge injection of 15 
mg/kg cocaine on the test day. Rats had received a 
test day injection of terguride (0.0, 0.2, 0.4, or' 0.8 
mg/kg, i.p.) 35 min prior to cocaine treatment.
During the pre-exposure phase, rats had received daily 
injections of saline (open symbols) or 30 mg/kg 
cocaine (filled symbols) (these are the same rats as 
describedin Fig. 8). Behavioral testing lasted 45 
min.
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mg/kg Terg/Coc group (filled circle) had significantly
more horizontal locomotor activity than the 0.4 mg/kg
Terg/Coc group (filled triangle).
A separate ANOVA was conducted to determine
whether the cocaine-pretreated control group (i.e.,
the cocaine group receiving 0.0 mg/kg terguride)
showed a sensitized locomotor response. Cocaine-
pretreated rats given cocaine and 0.0 mg/kg terguride
on the test day (filled circles, lower graph, Figure
10) exhibited significantly more locomotor activity
than saline-pretreated rats given cocaine and 0.0
mg/kg terguride (open circles, upper graph, Figure 10)
[Stimulant Condition main effect, F(l,7) = 6.90, p <
.05]. Thus, cocaine did produce locomotor
sensitization in the control subjects.
Experiment Four
Pre-Exposure Phase
Overall, rats treated with terguride had less
locomotor activity during the pre-exposure phase than
rats treated with saline [Drug Condition main effect,
F(6,42) = 3.21, p < .05]. This effect varied
according to test day, as the saline group (filled
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circle) had significantly more horizontal locomotor
activity than the terguride groups (other filled
symbols) on PD 15 and PD 16 [Drug Condition x Pre-
Exposure Day interaction, F(18,126). = 2.10, p < .05]
(see Figure 11). No group differences were observed
on PD 17-21.
Test Day
Overall, locomotor activity of- the cocaine-
treated rats declined rapidly over the first four time
blocks, at which time .it stabilized [Time main effect,
F(ll,77) = 36.50, p < .05] (see Figure 12). Terguride
pre-exposure did not affect the test day locomotor
activity of the rats. Thus, terguride alone is not
capable of inducing sensitized responding in young
rats.
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Figure 11. Mean ( + SEM) distance traveled (i.e., 
locomotor activity) of rats (n = 10 per group) 
receiving daily injections of terguride (0.4, 0.8, 
1.6 mg/kg, i.p.). Behavioral testing lasted 60 min
or
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Test Day
500
Figure 12. Mean (+ SEM) distance traveled (i.e., 
locomotor activity) of1 fats (n =’10' per group) 
receiving a challenge injection of saline (open 
symbols) or 0.4 mg/kg terguride (filled symbols) after 
one drug abstinence day (i.e.-, PD 23) . During the 
pre-exposure phase,'rats had received daily injections 
of terguride (0.0, 0.4, 0.8, or 1.6 mg/kg, i.p.)
(these are the same.rats as described in Fig. 11). 
Behavioral ‘ testing .lasted 60 min-. :
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CHAPTER FOURTEEN
DISCUSSION
The purpose of the present study was to
investigate whether a partial D2-like dopamine agonist
(i.e., terguride) would block the induction or
expression of cocaine-induced behavioral sensitization
in preweanling rats’. The ability of terguride to
induce behavioral sensitization was also examined, as
partial D2-like agonists have agonistic actions in
cases of low dopaminergic' tone (Clark, Furmidge et
al., 1991). It was originally hypothesized that
terguride would be effective in blocking both the
induction and expression of cocaine-induced behavioral
sensitization. It was also hypothesized that
terguride alone would be unable to induce behavioral
sensitization.
Results showed that a partial D2-like agonist
was unable to block the induction or ultimate
expression of cocaine-induced locomotor sensitization
in preweanling rats. Terguride partially attenuated 
cocaine-induced locomotion during the pre-exposure 
phase, however no dose completely eliminated locomotor
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activity. The induction of behavioral sensitization
was not blocked by terguride, as pups were able to
express a sensitized locomotor response when cocaine
was administered on the test day. Due to the large
dose range employed in this study (0.1-1.6 mg/kg), it
is unlikely that an insufficient dose of terguride was
used. Thus, these results indicate that a partial D2-
like agonist is unable to block the sensitization
component of the addiction process, even though it
does decrease the acute locomotor activating effects
of cocaine.
When terguride was administered on test day
(Experiment 3), pups showed a dose-dependent decrease
in cocaine-induced locomotor activity. This was true
of both saline- and cocaine-pretreated rats. Thus, it
is possible that terguride blocked the expression of 
behavioral sensitization to cocaine. Alternatively, 
it is possible that terguride caused a general
reduction in locomotor activity that was not related
to sensitization.
The ability of terguride to induce behavioral
sensitization was examined in Experiment 4. Results
showed that terguride (0.4-1.6 mg/kg) did not cause a
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day-dependent increase in locomotor activity, nor did
a test day challenge injection of terguride (0.4
mg/kg) cause a sensitized locomotor response. Thus,
repeated administration of terguride did not induce
behavioral sensitization in preweanling rats. Because
behavioral sensitization is a component of the
addiction processes (Di Chiara, 1995; Robinson, &
Berridge, 1993), these results suggest that terguride
lacks abuse potential. This conclusion is consistent
with studies showing that terguride does not maintain
self-administration in rats or rhesus monkeys
(Pulvirenti et al., 1998; Ranaldi et al., 2001).
In conclusion, partial D2-like receptor agonists
have both agonistic and antagonistic actions on G-
protein-coupled dopamine receptor sites (Hoyer &
Boddeke, 1993). In situations where dopaminergic
functioning is depressed, partial D2-like agonists
stimulate the dopamine system; whereas, in situations
where dopaminergic functioning is enhanced, partial D2-
like agonists depress the dopamine system (Clark,
Furmidge et al., 1991). Because of these
pharmacological characteristics, it was not surprising
that terguride partially attenuated the cocaine-
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induced locomotor activity of young rats. However, it
was surprising that terguride was unable to block the
induction of behavioral sensitization, especially
since partial D2-like agonists have previously been
shown to reduce the rewarding effects of cocaine and
other psychostimulants (see Bono et al., 1996; Izzo et
al., 2001; Pulvirenti et al., 1998). At present, it
remains unclear why neither the induction nor
expression of behavioral sensitization was blocked by
terguride administration, or why the cellular changes
believed to underlie behavioral sensitization were
apparently unaffected by this partial D2-like agonist.
There are several possibilities that may account for
these findings, including: the relative importance of
D2-like receptor stimulation for behavioral
sensitization, ontogenic differences in dopaminergic
substrates, and neuroplasticity.
Importance of D2-like Dopamine 
Receptor Stimulation for
Cocaine-Induced Behavioral 
Sensitization
A possible reason for terguride's lack of effect
is that D2-like dopamine receptor stimulation may not
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be necessary for cocaine-induced behavioral
sensitization. If true, neither a partial D2-like
agonist, nor a full D2-like receptor antagonist, should
block the induction of cocaine-induced behavioral
sensitization. Although this is the first study to
examine the effects of a partial D2-like agonist on
cocaine sensitization, many researchers have
administered D2-like receptor antagonist drugs prior to
pre-exposure or challenge injections of cocaine.
Surprisingly, these studies provide conflicting
results, as selective D2-like receptor antagonists have
alternately been reported to block the induction of
cocaine-induced sensitization (Mattingly, Rowlett,
Ellison, & Rase, 1996; Telia, 1994; Weiss et al.,
1989), or leave sensitization unaffected (Kuribara &
Uchihashi, 1993; Mattingly et al., 1994; White et al.,
1998). If, as the latter studies suggest, D2-like
receptor stimulation is unimportant for behavioral
sensitization, then it is not surprising that
terguride did not block the induction of cocaine-
induced sensitization. If, on the other hand, D2-like
receptor stimulation is necessary for cocaine-induced
behavioral sensitization, then terguride's inability
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to fully attenuate the locomotor activating effects of
cocaine may have permitted the induction process to
occur. Unfortunately, the present study is unable to
distinguish between these possibilities.
Ontogenic Differences
Another possible reason why terguride did not
block the induction of cocaine sensitization involves
the age of animals used. More specifically, there may
be ontological differences in how rats respond to
partial D2-like agonists, such as terguride. Across the
postnatal period dopamine systems undergo substantial
maturational changes (Gelbard et al., 1989; Jung &
Bennett, 1996). For example, Dx-like (Gelbard et al.,
1989; Giorgi et al., 1987) and D2-like (Murrin & Zeng,
1986; Schambra et al., 1994) binding sites increase in
number across the postnatal period. During the same
developmental period there is an increase in dopamine
levels (Coyle & Campochiaro, 1976; Giorgi et al.,
1987), as well as in increase in the number of
dopamine transporters (Bonnet & Costentin, 1989; Rao,
Molinoff, & Joyce, 1991) . In terms of function, Di-
like receptors are coupled to adenylyl cyclase by PD 1
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(Broaddus & Bennett, 1990; De Vries, Mulder, &
Schoffelmeer, 1992) and G-proteins by PD 5 (Jung &
Bennett, 1996); whereas, D2^like receptors are coupled
to adenylyl cyclase by PD 7 (Broaddus & Bennett, 1990;
De Vries et al.,,1992) and G-proteins by PD 1 (Sales,
Martes, Bouthernet, & Schwartz, 1991). Notably, an
adult-like interaction between dopamine Di- and D2-like
receptors is evident by PD 11 (McDougall, Arnold, &
Nonneman, 1990).
In terms of psychopharmacological actions,
dopamine-mediated behaviors are present in early
ontogeny. For example, administering a full dopamine
receptor agonist (e.g., apomorphine and guinpirole) as
early as PD 4 increases the locomotor activity of rat
pups (Camp & Rudy, 1987; Moody & Spear, 1992).
Further, administering a direct D2-like dopamine
receptor antagonist (e.g., sulpiride), reduces the
locomotor activity of young (McDougall et al., 1990),
as well as adult rats (Neiswander, O'Dell, & Redmond,
1995). Dopamine systems mediating reward also become
functionally mature early in ontogeny, since cocaine
and amphetamine potentiate intracranial self­
administration by PD 3 (Barr & Lithgow, 1986), and
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cocaine supports conditioned place preferences by PD
10 (Pruitt, Bolanos, & McDougall, 1995). Therefore,
available evidence suggests that while dopamine
systems are maturing across the postnatal period, they
are capable of mediating behavior in an adult-like
manner. For this reason, it seems that immaturity of
the dopamine system is an unlikely explanation for why
terguride did not block the induction of cocaine-
induced behavioral sensitization.
Neuroplasticity
Another explanation for terguride's lack of
effect involves the neuroplasticity characteristic of
younger animals. Developmental neuroplasticity allows
for reorganization of neurons in a manner that is not
observed in adult animals, and may serve to make brain
less vulnerable to endogenous (e.g., developmental
defect) or exogenous (e.g., drug-induced) damage
(Weiss et al., 1989). Receptor formation and
replacement occurs at a higher rate in the striatum of
younger animals, and synaptic formations are more
easily corrupted or changed than in the adult (Fassano
& Brambilla, 2002).
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Empirical evidence has shown that neuroplasticity
is evident across ontogeny in both non-human animals
and humans. For example, young kittens that are
monocularly or binocularly deprived of vision show
evidence of robust plasticity in brain areas mediating
vision (Hubei & Wiesel, 1967, 1970). After monocular
deprivation, there is an increase in cortical cells
involving the sighted eye, along with increased
lateral geniculate nucleus (LGN) terminals in striatal
cells normally utilized by neurons from the non-
sighted eye (Hubei & Wiesel, 1967, 1970). This
finding provides evidence that environmental
influences induce neuroplasticity during early
ontogeny. Environmental deprivation can also result
in a neuroplastic response (Greenough & Chang, 1989).
Rats raised in an isolated environment show 20-25%
fewer synaptic connections than rats raised in an
enriched environment (Oppenheim, 1985). In humans,
brain damaged children have been shown to recover from
brain damage that would induce aphasia in adults
(Alajouanine & L'Hermittee, 1965). This type of 
recovery of function occurs most robustly before 5
years of age, and seldom occurs after 8 years of age
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(Kolb & Whishaw, 1989). This time frame of enhanced
neuroplasticity (0-5 years in humans and 0-30 days in
rats) is coincident with the time that brain undergoes
substantial neuronal maturation, refinement, and
development (Fassano & Brambilla, 2002).
Based on the general evidence cited above, it is
possible that there are neuroplastic changes in the
neural circuitry of young rats that permit the
induction of behavioral sensitization despite the
administration of a partial D2-like agonist drug. More
specifically, terguride may be unable to block the
induction of behavioral sensitization because other
neural circuits are capable of compensating for the D2-
like receptor blockade. Consistent with the
explanation, mice, genetically engineered to lack the Di
receptor (i.e., the receptor is missing since initial
fertilization) show amphetamine-induced behavioral
sensitization (Crawford et al., 1997; Karper, De La
Rosa, Newman, Krall, Nazarian, ' McDougall, & Crawford,
2002). This indicates that neural processes systems 
underlying behavioral- sensitization are capable of
showing a robust compensatory response.
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Lastly, one of the most consistent findings in
this study was that terguride attenuated the cocaine-
induced horizontal locomotor activity of rat pups.
Wise and Bozarth (1987) have posited that the
addictive potential of a drug is related to its
ability to induce locomotion. If true, attenuation of
psychostimulant-induced locomotor activity may
indicate that the rewarding effect of the
psychostimulant is diminished. Thus, terguride's
ability to reduce cocaine-induced locomotor activity
may indicate that this'partial D2-like agonist is
capable of disrupting other aspects of the addiction
process. It is possible, therefore, that terguride
may be efficacious for treating psychostimulant
addiction by impacting process (i.e., not involving
behavioral sensitization) that contributes to reward
or reinforcement.
Summary
Terguride did not block the induction of
behavioral sensitization in young rats. These 
findings are not in accordance with past self­
administration studies showing that terguride is
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capable of-blocking the reward process. Possible
reasons for terguride's lack of effect include: the
relative importance of D2-like receptor stimulation for
behavioral sensitization, ontogenic differences in
dopaminergic substrates, and neuroplasticity. The
present results bring into question whether terguride
will prove useful as a pharmacotherapy for
psychostimulant addiction. On the one hand, terguride
appears promising because it blocks the self­
administration of psychostimulants, however it does
not block the induction of cocaine-induced behavioral
sensitization in young animals. Importantly, the drug
self-administration and behavioral sensitization
paradigms model different aspects of the addiction
process, so it is likely that a pharmacotherapy
involving terguride may still be of benefit for the
treatment of psychostimulant addiction. Finally, It
is possible that terguride may be able to modulate
ancillary processes of addiction that contribute to
reward and reinforcement.
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